CXCR4-IN-3 (compound XVI) is an orally active inhibitor targeting the inflammation-related receptor CXCR4, with an IC50 of 3.2 nM. It exhibits potent anti-chemotactic effects, with an inhibition rate of 79.19±2.33%. Additionally, CXCR4-IN-3 possesses anti-inflammatory properties and can be utilized in research on IBD (inflammatory bowel disease).

CXCR4:3.2 nM

CXCR4-IN-3 (compound XVI) administered at 25 mg/kg orally twice daily for 14 days can alleviate DSS (dextran sulfate sodium)-induced IBD (inflammatory bowel disease), and is associated with a reduction in the number of inflammatory cells and decreased secretion of inflammatory factors. CXCR4-IN-3, administered intravenously at 2 mg/kg or orally at 20 mg/kg once, demonstrates reasonable pharmacokinetic properties.